Sara Giuliano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Giuliano has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Tersigni
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito, 8, 00168, Rome, Italy
2 shared publications Giovanni Scambia
Dipartimento di Scienze della Salute della Donna del Bambino e di Sanità Pubblica Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Rome Italy
2 shared publications- Nicoletta Di Simone
Department of Biomedical Sciences Humanitas University Milan Italy
2 shared publications - Silvia D'IPpolito
Department of Medicine and Health Science “V. Tiberio”, University of Molise, 86100 Campobasso, Italy
2 shared publications - Ahmed Salaheldin Zaki Moustafa
Division of Maternal‐Fetal Medicine Department of Obstetrics Gynecology and Reproductive Sciences McGovern Medical School at UTHealth Houston Houston Texas USA
1 shared publication - Alessio Colalillo
Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
1 shared publication
Latest Publications
- Open Access
The role of serial blood tests during expectant management of early preeclampsia with severe features
Background: Expectant management of early‐onset preeclampsia with severe features (N = 325; 87.8%; 95% CI, 84.1–91.0). For 40 patients (10.8%; 95% CI, 7.8–14.4), blood test abnormalities were detected after decision for delivery was made. The median number of blood tests per patient was 10 (IQR 6–14), and blood testing charge per patient was $5030 (IQR 3018–7042). The total charge for blood testing was $2.176 million over the study period. Conclusion: Among 370 patients with early‐onset preeclampsia with severe features managed expectantly, only 1% of the cohort had blood test abnormalities as the sole indication for delivery. All other patients were delivered either because of maternal‐fetal indications or developed blood test abnormalities occurring in association with other indications for delivery. Finally, serial blood testing in this setting resulted in total charges of $2.176 million over 9 years. Based on this large cohort, there is a need to reconsider the frequency of blood testing in the absence of new‐onset symptoms or worsening severe features.
Open AccessThe role of serial blood tests during expectant management of early preeclampsia with severe features
Background: Expectant management of early‐onset preeclampsia with severe features (N = 325; 87.8%; 95% CI, 84.1–91.0). For 40 patients (10.8%; 95% CI, 7.8–14.4), blood test abnormalities were detected after decision for delivery was made. The median number of blood tests per patient was 10 (IQR 6–14), and blood testing charge per patient was $5030 (IQR 3018–7042). The total charge for blood testing was $2.176 million over the study period. Conclusion: Among 370 patients with early‐onset preeclampsia with severe features managed expectantly, only 1% of the cohort had blood test abnormalities as the sole indication for delivery. All other patients were delivered either because of maternal‐fetal indications or developed blood test abnormalities occurring in association with other indications for delivery. Finally, serial blood testing in this setting resulted in total charges of $2.176 million over 9 years. Based on this large cohort, there is a need to reconsider the frequency of blood testing in the absence of new‐onset symptoms or worsening severe features.
- Open Access
- 21 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8275
Response to Misoprostol Treatment in Early Pregnancy Loss: A Single-Center Prospective Observational Study
Introduction: Medical treatment with misoprostol represents one of the main treatments for Early Pregnancy Loss (EPL). In our study, we aimed to identify clinical features associated with a successful response to this approach. Methods: A prospective single-center observational study was conducted at the EPL Clinic of the Department of Obstetrics and Gynecology, Fondazione A. Gemelli IRCCS Rome, Italy. Patients were categorized according to the type of treatment received: spontaneous delivery, elective dilatation and curettage, or medical treatment. A separate analysis was performed within the medical treatment group to distinguish women with a successful response from those with an unsuccessful one. The success of medical treatment was calculated as the response rate (number of patients who successfully responded to treatment/total number of treated patients) with a 95% Confidence Interval (CI). For patients undergoing misoprostol treatment, a multivariable analysis was planned to identify predictors of a successful response, including variables with a p value less than 0.05 in the univariable analysis. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive ability of continuous obstetrics parameters for medical treatment success. The optimal cut-off value to differentiate responsive from unresponsive patients was also determined. The significance level was set at p < 0.05. Results: Sixty-four patients who underwent medical treatment were analyzed. Amenorrhea age was the only parameter inversely associated with treatment success, indicating that an earlier amenorrhea age correlated with a better response to misoprostol. ROC analysis identified a cut-off of 62.5 days, with an AUC (95% CI) of 0.72 (0.55–0.89). An amenorrhea age of ≤ 62.5 days predicted a successful response to medical treatment with a specificity (95% CI) of 90.0% (89.8–90.2) and sensitivity (95% CI) of 54.9% (41.2–68.6). Conclusions: Amenorrhea age emerged as a potential predictor of treatment response in women with EPL undergoing misoprostol therapy. However, further studies of larger sample sizes are needed to validate and improve our model.
- 21 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8275
Open AccessResponse to Misoprostol Treatment in Early Pregnancy Loss: A Single-Center Prospective Observational Study
Introduction: Medical treatment with misoprostol represents one of the main treatments for Early Pregnancy Loss (EPL). In our study, we aimed to identify clinical features associated with a successful response to this approach. Methods: A prospective single-center observational study was conducted at the EPL Clinic of the Department of Obstetrics and Gynecology, Fondazione A. Gemelli IRCCS Rome, Italy. Patients were categorized according to the type of treatment received: spontaneous delivery, elective dilatation and curettage, or medical treatment. A separate analysis was performed within the medical treatment group to distinguish women with a successful response from those with an unsuccessful one. The success of medical treatment was calculated as the response rate (number of patients who successfully responded to treatment/total number of treated patients) with a 95% Confidence Interval (CI). For patients undergoing misoprostol treatment, a multivariable analysis was planned to identify predictors of a successful response, including variables with a p value less than 0.05 in the univariable analysis. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive ability of continuous obstetrics parameters for medical treatment success. The optimal cut-off value to differentiate responsive from unresponsive patients was also determined. The significance level was set at p < 0.05. Results: Sixty-four patients who underwent medical treatment were analyzed. Amenorrhea age was the only parameter inversely associated with treatment success, indicating that an earlier amenorrhea age correlated with a better response to misoprostol. ROC analysis identified a cut-off of 62.5 days, with an AUC (95% CI) of 0.72 (0.55–0.89). An amenorrhea age of ≤ 62.5 days predicted a successful response to medical treatment with a specificity (95% CI) of 90.0% (89.8–90.2) and sensitivity (95% CI) of 54.9% (41.2–68.6). Conclusions: Amenorrhea age emerged as a potential predictor of treatment response in women with EPL undergoing misoprostol therapy. However, further studies of larger sample sizes are needed to validate and improve our model.
- Open Access
- 30 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10)
Cell Salvage in the Management of Postpartum Hemorrhage: A Comprehensive Review of the Current Literature
Postpartum hemorrhage (PPH) remains a leading contributor in maternal illness and death worldwide, and its incidence continues to rise. This has led to an increased reliance on allogeneic blood transfusions (ABT), which are limited in supply and carry significant health risks. Cell salvage (CS), which collects and transfuses a patient’s own blood, has been proposed as a useful adjunct or alternative. This narrative review aims to evaluate and summarize the current literature on obstetric CS (OCS) in the management of PPH, with a focus on efficacy, safety, cost-effectiveness, and future research considerations. A literature search was performed using PubMed and Google Scholar, leading to the selection and review of 32 original articles published from 2015 onward. Single case reports, meta-analyses, and other review articles were excluded to minimize amplification bias and ensure an authentic analysis of primary research data. OCS has been shown to reduce the need for donor blood, especially during high-risk cesarean sections, including those with placenta previa and placenta accreta spectrum. Reported benefits include improved maternal hemoglobin, reduced transfusion-related complications, and shorter hospital stay. However, not all the results were statistically significant for reductions in allogeneic transfusion rates. Safety concerns associated with the use of OCS, including amniotic fluid embolism, sepsis, hemolysis, coagulopathy, and Rh alloimmunization, have been substantially addressed through advancements in technology, the implementation of leukocyte depletion filters, and the routine administration of anti-D prophylaxis. Evidence for its use in vaginal deliveries remains sparse, though early studies suggest technical feasibility. Cost-effectiveness is debated and appears dependent on institutional protocols, case volume, and technique optimization. OCS represents a safe and valuable blood-conservation strategy in obstetric practice, particularly for high-risk cesarean section. Wider adoption requires standardized protocols, staff training, and further multicenter research to clarify its role, especially in vaginal deliveries.
- 30 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10)
Open AccessCell Salvage in the Management of Postpartum Hemorrhage: A Comprehensive Review of the Current Literature
Postpartum hemorrhage (PPH) remains a leading contributor in maternal illness and death worldwide, and its incidence continues to rise. This has led to an increased reliance on allogeneic blood transfusions (ABT), which are limited in supply and carry significant health risks. Cell salvage (CS), which collects and transfuses a patient’s own blood, has been proposed as a useful adjunct or alternative. This narrative review aims to evaluate and summarize the current literature on obstetric CS (OCS) in the management of PPH, with a focus on efficacy, safety, cost-effectiveness, and future research considerations. A literature search was performed using PubMed and Google Scholar, leading to the selection and review of 32 original articles published from 2015 onward. Single case reports, meta-analyses, and other review articles were excluded to minimize amplification bias and ensure an authentic analysis of primary research data. OCS has been shown to reduce the need for donor blood, especially during high-risk cesarean sections, including those with placenta previa and placenta accreta spectrum. Reported benefits include improved maternal hemoglobin, reduced transfusion-related complications, and shorter hospital stay. However, not all the results were statistically significant for reductions in allogeneic transfusion rates. Safety concerns associated with the use of OCS, including amniotic fluid embolism, sepsis, hemolysis, coagulopathy, and Rh alloimmunization, have been substantially addressed through advancements in technology, the implementation of leukocyte depletion filters, and the routine administration of anti-D prophylaxis. Evidence for its use in vaginal deliveries remains sparse, though early studies suggest technical feasibility. Cost-effectiveness is debated and appears dependent on institutional protocols, case volume, and technique optimization. OCS represents a safe and valuable blood-conservation strategy in obstetric practice, particularly for high-risk cesarean section. Wider adoption requires standardized protocols, staff training, and further multicenter research to clarify its role, especially in vaginal deliveries.
- Top Cited Papers
- 8 January 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 93 (1) , e70037
Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta‐Analysis
Recurrent pregnancy loss (RPL) represents a complication of pregnancy occurring in 1%–3% of all couples trying to conceive. About 50%–60% of RPL cases remain idiopathic, therefore therapeutic strategies seem empirical and based on unproven evidence. We investigated the efficacy of corticosteroids in women with RPL. We conducted a systematic review and meta‐analysis, up to August 2024, in the PubMed, Scopus, and Web of Science databases, including studies on idiopathic RPL women and comparing corticosteroids versus control treatment. Primary outcome was the ongoing pregnancy rate beyond 12 weeks of gestation; secondary outcomes were live birth rate (LBR), stillbirth, birth weight, incidence of preeclampsia and/or gestational diabetes, gestational age at delivery, and fetal abnormalities. Four studies comprising 417 RPL women randomly assigned to steroid or control treatment were included. We found that oral corticosteroids significantly increase the ongoing pregnancy rate beyond 12 weeks of gestation compared to the control group (log OR [odds ratio] = 1.49 [0.32, 2.67], p = 0.01), with high heterogeneity (I2 = 75%), and improve LBR (log OR = 0.9 [0.11, 1.69], p = 0.03), with low heterogeneity (I2 = 0.05%). However, the limited number of studies significantly limits the strength of the findings. Also, the benefit/risk assessment of the use of corticosteroids in early pregnancy for RPL is still unclear.
- 8 January 2025
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 93 (1) , e70037
Top Cited PapersEfficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta‐Analysis
Recurrent pregnancy loss (RPL) represents a complication of pregnancy occurring in 1%–3% of all couples trying to conceive. About 50%–60% of RPL cases remain idiopathic, therefore therapeutic strategies seem empirical and based on unproven evidence. We investigated the efficacy of corticosteroids in women with RPL. We conducted a systematic review and meta‐analysis, up to August 2024, in the PubMed, Scopus, and Web of Science databases, including studies on idiopathic RPL women and comparing corticosteroids versus control treatment. Primary outcome was the ongoing pregnancy rate beyond 12 weeks of gestation; secondary outcomes were live birth rate (LBR), stillbirth, birth weight, incidence of preeclampsia and/or gestational diabetes, gestational age at delivery, and fetal abnormalities. Four studies comprising 417 RPL women randomly assigned to steroid or control treatment were included. We found that oral corticosteroids significantly increase the ongoing pregnancy rate beyond 12 weeks of gestation compared to the control group (log OR [odds ratio] = 1.49 [0.32, 2.67], p = 0.01), with high heterogeneity (I2 = 75%), and improve LBR (log OR = 0.9 [0.11, 1.69], p = 0.03), with low heterogeneity (I2 = 0.05%). However, the limited number of studies significantly limits the strength of the findings. Also, the benefit/risk assessment of the use of corticosteroids in early pregnancy for RPL is still unclear.
- 1 November 2023
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 75 (6) , 896-904
The impact of glucocorticoids on bone health and growth: endocrine and non-endocrine effects in children and young patients
Article: The impact of glucocorticoids on bone health and growth: endocrine and non-endocrine effects in children and young patients - Minerva Pediatrics 2022 Oct 31 - Minerva Medica - Journals
- 1 November 2023
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 75 (6) , 896-904
The impact of glucocorticoids on bone health and growth: endocrine and non-endocrine effects in children and young patients
Article: The impact of glucocorticoids on bone health and growth: endocrine and non-endocrine effects in children and young patients - Minerva Pediatrics 2022 Oct 31 - Minerva Medica - Journals